Field notes on the work that actually happens between RFI and First Patient In, from the team building the infrastructure for it.
Capability is a corporate fact. Delivery is what these specific people do for this specific protocol when the plan breaks.
Read the essay →We bet on the infrastructure that runs clinical trials today and will still run them tomorrow.
Read the essay →We let the complaint dictate what we build. But SSO is a falsche Fährte, a false trail. The real problem is somewhere else.
Read the essay →Clinical trials today are still prototypes. Ford’s revolution wasn’t the car. It was the assembly line.
Read the essay →The silence between “site selected” and “site activated” costs about $80,000 a day, and sometimes a patient’s last good option.
Read the essay →Drugs once reached patients in months. A journey back to the era before regulation tightened its grip.
Read the essay →Sites are the atomic unit of clinical development. Yet no company has a structured view of the quality of its relationships with them.
Read the essay →The most valuable data isn’t in your lab notebooks. It’s in how you select, engage, and contract with your sites.
Read the essay →New essays on the work between RFI and First Patient In, direct to your inbox.
Subscribe →Customer stories worth borrowing. Insights worth keeping. The work that actually happens between RFI and First Patient In, direct to your inbox.
Subscribe →Tell us where Yendou can move your next bid, or your next study. We read every message.
We use essential cookies to run this site. With your consent, we also use analytics cookies to understand how the site is used and improve it. See our Cookie Policy.